Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Capital Expenditures (2016 - 2025)

Adma Biologics' Capital Expenditures history spans 13 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 60.68% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $22.6 million, up 174.43%, while the annual FY2025 figure was $22.6 million, 174.43% up from the prior year.
  • Capital Expenditures reached $1.1 million in Q4 2025 per ADMA's latest filing, down from $14.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $14.4 million in Q3 2025 to a low of $757000.0 in Q3 2023.
  • Average Capital Expenditures over 5 years is $3.1 million, with a median of $2.7 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: crashed 77.87% in 2023, then soared 1260.61% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $3.7 million in 2021, then rose by 1.98% to $3.7 million in 2022, then crashed by 68.07% to $1.2 million in 2023, then surged by 130.33% to $2.8 million in 2024, then crashed by 60.68% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Capital Expenditures are $1.1 million (Q4 2025), $14.4 million (Q3 2025), and $2.4 million (Q2 2025).